Denali therapeutics announces key anticipated 2024 milestones and priorities to further advance its therapeutics portfolio for neurodegeneration and lysosomal storage diseases

South san francisco, calif., jan. 08, 2024 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced program progress and expected milestones for 2024, which chief executive officer, ryan watts, ph.d., will highlight during a corporate presentation at the 42nd annual j.p. morgan healthcare conference on tuesday, january 9th, at 10:30 a.m. pacific time.
DNLI Ratings Summary
DNLI Quant Ranking